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Mammography screening trial results
Screening shifts the balance of breast cancers from mainly
palpable to mainly impalpable. Randomized controlled mam-
mography screening trials have unequivocally demonstrated
the following.
• Screening for breast cancer can prevent death from the
disease.
￿ Breast cancer is not a systemic disease from the outset.
￿ Breast cancer is a progressive disease, but progression
can be arrested by early detection and treatment at a
sufficiently early phase.
￿ The major factor determining the final outcome is the
timing of treatment relative to the natural history of the
disease, rather than the choice of treatment offered to
breast cancer patients.
￿ Because breast cancer is not a systemic disease from
inception, when it is detected as either an in situ or a 1 to
14 mm invasive tumour it is primarily a surgical disease.
The revolution in detecting breast cancer at these early
stages awaits a similar revolution in therapy.
￿ Guidelines for the treatment of breast cancer detected at
screening should not be based on trial results obtained in
palpable, clinically detected cancers. There is con-
siderable risk for over-treatment if the adjuvant treatment
regimens that have been developed to treat palpable
cancers are also used to treat mammographically
detected, nonpalpable ‘baby cancers’. To quote Cady and
Chung [1], ‘The reduction in need for radiation and
systemic adjuvant chemotherapy, which are both expen-
sive and toxic, is made possible by detecting T1a and T1b
breast cancers.’
Summary
The mammographic screening trials have clearly demon-
strated the life-saving effect of early breast cancer detection
and removal, combined with reduced need for adjuvant
treatment regimens.
Value of mammographic prognostic features
Despite the excellent prognosis of most patients with small
breast cancers, a small number of women still die from
tumours of 1 to 14 mm a few years after diagnosis. When
searching for features that are common to these rare fatal
cancers, neither axillary node status nor histologic malignancy
grade could reliably discriminate fatal cancers from those
with excellent prognosis. We have found the mammographic
image to be a reliable reflection of breast structure, although
it tends to simplify the histological heterogeneity of breast
cancer to five mammographic tumour features (Figure 1) [2].
Analysis of these features shows them to be reliable
additional prognostic tools for predicting the long-term out-
come of early breast cancers [2-4].
Although axillary node status and histological malignancy grade
are established and reliable prognostic factors in tumours
larger than 20 mm, the predictive value of these factors is
reduced at sizes under 15 mm. Tumours that present with
casting type calcifications on the mammogram have exhibited a
surprisingly poor outcome, even when they are node negative,
which demonstrates the prognostic value of this particular
mammographic tumour feature when estimating patient
outcome. Also, the diminished reliability of the histological
malignancy grade was demonstrated in a series consisting of
440 consecutive cases of 1 to 9 mm breast cancer in women
aged 40 to 69 years and followed up for as long as 26 years.
There was a significantly poorer long-term survival in women
with grade 2 invasive breast cancer than in those with 1 to
9 mm grade 3 breast cancers. However, the addition of the
mammographic tumour features allows us to divide the grade 2
tumours into two subgroups that have vastly different
outcomes. Women lacking calcifications had 100% long-term
survival, whereas the association of extensive, grade 3 in situ
breast cancer presenting on the mammogram as casting type
calcifications with 1 to 9 mm grade 2 invasive breast cancer
led to a surprisingly poor long-term survival [2-4] (Figure 2).
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The integration of mammographic tumour features into the
TMN staging system should enable practising physicians to
distinguish more accurately between the 1 to 14 mm breast
cancers with extremely good long-term prognosis and those
cases with unexpectedly poor prognosis, allowing them to use
more specifically targeted therapy and to avoid overtreatment.
The 26-year survival rates of women with 1 to 9 mm and 10
to 14 mm invasive breast cancers associated with casting type
calcifications were 49% and 54%, respectively. This finding
suggests that 1 to 14 mm breast cancers that are associated
with casting type calcifications should belong to a more
advanced stage category that reflects their clinical behaviour.
The casting type calcifications are found within the abnormal,
closely packed, contorted, newly formed ducts, which we
consider to be duct-forming invasive carcinoma and have
termed ‘neoductgenesis’ [2,3]. It appears that vascular
intrusion may occur during this process of neoductgenesis,
leading to histologically demonstrable extensive lymphatic
and/or haematogenous spread. On the other hand, stellate/
spiculated 1 to 9 mm tumours without associated calcifica-
tion, which comprised the largest group (50%) in this size
range, had the greatest long-term survival (99%). After
exclusion of 1 to 9 mm cancers associated with casting type
calcifications, the remaining cancers have extremely good
prognosis when they are treated with surgery alone. Adjuvant
therapeutic regimens offer little to no benefit to these patients
and have the potential for causing harm [2,5].
Summary
The mammographic tumour features can serve as indepen-
dent predictors of long-term outcome in screen-detected 1 to
14 mm invasive breast cancers.
Modern histological examination of breast
tissue requires the introduction of large thin
section and subgross/three-dimensional
histological techniques
Modern imaging tools, breast magnetic resonance imaging
included, are of great value in preoperative mapping of the
true extent of breast cancer, and they are an essential
component of treatment planning. Adequate correlation of
imaging findings with underlying histology requires large thin
section and large thick section, subgross (three-dimensional)
histological examination. Large section histology permits the
examination of about 65 cm2 of contiguous tissue; in com-
parison, standard glass slides cover an area of only about
5c m 2, greatly limiting reliable evaluation of tumour size and
extent. The piecemeal reconstruction of a tumour’s size,
shape and margins, which every pathologist must do
mentally, can hardly be considered to have a realistic 1:1
correlation with modern imaging methods, such as mammo-
graphy, breast ultrasound and magnetic resonance imaging.
Also, less than 20% of the specimen’s margin is examined
when the conventional, small block histology technique is
used (Tucker L, personal communication). Large section
histology leads to a more accurate documentation of the main
tumour and the surrounding tissue, which may contain
additional invasive and/or in situ cancer foci and permits
more accurate assessment of the margins [5].
Summary
The correlation of modern imaging techniques with large
section histology will lead to a considerably improved
mapping of disease extent, which in turn will result in more
appropriate treatment, fewer recurrences, and consequently
better patient care.
Local recurrence is not a predictor of poor
outcome when the primary tumour and local
recurrence are both nonpalpable and have
been detected by imaging
Palpable breast cancers that recur locally tend to have poor
survival. Experience with such tumours has given physicians
Figure 1
The five mammographic prognostic features.
Figure 2
The influence of casting type calcifications on survival. Shown is the
survival of women with 1 to 9 mm grade 2 stellate tumours with and
without associated casting type calcifications.Page 3 of 3
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an ingrained fear of local recurrence, but radiotherapy has its
own risks [6]. However, the harm/benefit ratio of adjuvant
radiotherapy increases with decreasing tumour size.
Randomized controlled trials evaluating the impact of post-
operative radiation therapy on both local recurrence and long-
term survival in mammographically detected, under 20 mm,
node-negative, unifocal breast cancers have demonstrated
that the addition of radiotherapy made no difference to long-
term outcome. Using these selection criteria, radiotherapy
was found to have no impact on breast cancer survival in the
Örebro-Uppsala trial, despite a 15% higher local recurrence
in the non-irradiated group of patients [7]. Further
confirmatory data have been reported [8,9]. Because the vast
majority of screen-detected breast cancer cases are unlikely
to benefit from postoperative irradiation, it is important to
define this subgroup of patients. Use of mammographic
tumour features plays an important role in this selection [2].
Summary
In screen-detected breast cancers, when local recurrence is
also found at regular surveillance it has no negative impact on
long-term outcome.
Conclusion
Population-based mammography screening has brought
about a paradigm shift in our approach to the diagnosis and
treatment of breast cancer. The spectrum of the disease has
shifted from primarily palpable, advanced cancer to mainly
impalpable tumours that have exceedingly good prognosis.
The traditional emphasis upon applying therapeutic regimens
designed for advanced disease should give way to a new
emphasis upon less radical and tailored treatments, whenever
disease progression to advanced stages has successfully
been arrested through early detection.
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